Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticleClinical Review

Approach to chronic obstructive pulmonary disease in primary care

David C. Todd, R. Andrew McIvor, Stewart O. Pugsley and Gerard Cox
Canadian Family Physician May 2008; 54 (5) 706-711;
David C. Todd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Andrew McIvor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amcivor@stjosham.on.ca
Stewart O. Pugsley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard Cox
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

OBJECTIVE To review the diagnosis, assessment of severity, and management of chronic obstructive pulmonary disease (COPD) and to address the systemic manifestations associated with COPD.

SOURCES OF INFORMATION PubMed was searched from January 2000 to December 2007 using the key words COPD, practice guidelines, randomized controlled trials, therapy, and health outcomes. The Canadian Thoracic Society guideline on management of COPD was carefully reviewed. The authors, who have extensive experience in care of patients with COPD, provided expert opinion.

MAIN MESSAGE Chronic obstructive pulmonary disease is a common systemic disease caused primarily by smoking. Spirometry is essential for diagnosis of COPD and should be integrated into primary care practice. Pharmacologic and nonpharmacologic therapy improves symptoms, capacity for exercise, and quality of life. Smoking cessation is the only intervention shown to slow disease progression. The systemic manifestations and comorbidity associated with COPD need to be identified and addressed to optimize health and quality of life.

CONCLUSION An evidence-based approach to managing COPD along with a primary care chronic disease management model could improve quality of life for patients with COPD.

Chronic obstructive pulmonary disease (COPD) is a systemic disorder caused mainly by smoking and is characterized by progressive irreversible, or partially reversible, airflow obstruction; systemic manifestations; and recurrent exacerbations.1 Respiratory symptoms include dyspnea, wheezing, coughing, and sputum production. Systemic features include skeletal muscle dysfunction and hence limited ability to exercise,2,3 weight loss, depression and anxiety,4 osteoporosis,5 increased risk of cardiovascular disease6 including right heart failure, and polycythemia.

Most cases (85% to 90%) are due to cigarette smoking. Other causes include exposure to air pollutants and environmental toxins and hereditary factors, such as α1-antitrypsin deficiency. Reports indicate that at least 10% to 15% of smokers will be diagnosed with COPD based on conventional diagnostic strategies, although this is likely an underestimation of the proportion of smokers with COPD.

In Canada, COPD is a prevalent condition and is associated with substantial negative effects on health.7 Evidence from recent literature provides an approach to managing COPD that acknowledges the systemic manifestations of the disease and the many comorbidities that accompany it. Primary care providers have a unique opportunity to identify patients at risk through directed screening, to implement primary and secondary prevention strategies, and to provide care that encompasses a holistic approach to management. As the population ages, the burden of illness from COPD is expected to increase. Application of a simple approach to identifying and managing COPD could substantially improve patient care and the efficiency of practice.

Case description

A 58-year-old female smoker presents complaining of dyspnea associated with chronic cough and sputum production during the winter months. Her general health is good, and she is not taking any medications. She recently took early retirement to spend more time golfing but finds she is too short of breath to play more than 9 holes even though she now has the time. She gets breathless walking up a slight hill. She is 1.64 m tall, weighs 65 kg, and has a body mass index of 24. Results of respiratory and cardiac examinations are normal. Chest radiography shows hyperinflation. Office spirometry reveals moderate airflow obstruction.

Sources of information

PubMed was searched from January 2000 to December 2007 using the key words COPD, practice guidelines, randomized controlled trials, therapy, and health outcomes. The Canadian Thoracic Society’s guideline on management of COPD was reviewed extensively, and some of the references published before 2003 were gathered from this document. The approach we describe was developed based on the clinical experience of the authors and is supported by evidence when referenced. Generally, the recommendations on pharmacologic and nonpharmacologic therapy are based on data from randomized controlled trials (level I evidence).

Screening and diagnosis

Screening can be carried out with simple office spirometry. All smokers and ex-smokers 40 years old and older should be screened. Screening with spirometry is underused in primary care, and health care providers should consider developing a way of identifying smokers and ex-smokers in their practices in order to ensure that these patients are offered screening for COPD. Ways to identify these patients include flagging charts or using computerized reminders, particularly during periodic health visits. A recent prospective observational study that screened 818 smokers older than 40 with no known diagnosis of COPD found a prevalence of COPD of 18.9%.8 More than 40% of those with COPD had moderate to severe impairment in lung function. These results are consistent with those of other studies that have reported a prevalence of COPD of 7.4% to 18% in general practice.9,10 Preliminary results from the multinational Burden of Obstructive Lung Disease (BOLD) study demonstrated a prevalence of COPD of 10.7% based on a forced expiratory volume of air in 1 second (FEV1) of < 80% and an FEV1–forced vital capacity ratio of < 0.7.11 Spirometry is inexpensive and is supported financially through most provincial health care programs. Although the cost-effectiveness of office spirometry has not been established,12 the early diagnosis it provides will identify patients who require more aggressive interventions aimed at smoking cessation and allow implementation of pharmacologic and nonpharmacologic therapy.

A diagnosis of COPD requires a postbronchodilator FEV1–forced vital capacity ratio of < 0.7. If this parameter normalizes over time, then the diagnosis must be withdrawn and an alternative diagnosis considered.1

Classification of severity and prognosis

Once the diagnosis is confirmed, patients should be carefully evaluated to identify factors contributing to the disease, the effect of COPD on their lives, and prognosis (Table 1). Potential systemic manifestations of the disease must be identified, as they might strongly influence decisions about treatment. These systemic manifestations include pulmonary hypertension and cor pulmonale, coronary artery disease, hypercapnia, osteopenia or osteoporosis, peripheral muscle dysfunction and low body mass index, depression and anxiety, and concomitant eosinophilic bronchitis.

View this table:
  • View inline
  • View popup
Table 1

Initial evaluation of patients diagnosed with chronic obstructive pulmonary disease

Traditionally, the severity of COPD has been classified based on the degree of reduction in FEV1. While FEV1 is a useful measure, it does not accurately predict capacity for exercise13 or survival as well as other measures, such as formal laboratory-based exercise testing or symptoms of dyspnea.14 Measures other than FEV1 should be used to establish disease severity in primary care practice. These measures include evaluating the degree of dyspnea using the modified Medical Research Council (MRC) dyspnea scale15 or BODE index.

Dyspnea is a frequent symptom in COPD, and a simple classification scheme modified from the MRC dyspnea scale (Table 215) can assist in identifying the severity of disease.1 The scale can be easily and efficiently applied in an office setting.

View this table:
  • View inline
  • View popup
Table 2

Modified Medical Research Council dyspnea scale

Chronic obstructive pulmonary disease is a major cause of morbidity and mortality. The long-term prognosis in most patients indicates progressive deterioration in lung function and increased systemic manifestations. Severity of dyspnea and capacity for exercise are more predictive of mortality than FEV1 is.14,16 The BODE index17 is a multidimensional tool that has been shown to predict survival based on body mass index (< 21 is associated with greater mortality), FEV1 (airflow obstruction), degree of dyspnea (MRC grade), and capacity for exercise (6-minute walk distance). The BODE score is useful in establishing prognosis and severity of disease,17,18 is responsive to respiratory rehabilitation,19 predicts risk of hospitalization for COPD patients better than FEV1 does,20 and is sensitive to change following exacerbations.21 In primary care, the BODE score gives an estimate of prognosis and, therefore, might be helpful in determining which patients should be considered for more aggressive therapy and follow-up. The BODE index is also useful for identifying response to certain interventions. Patients who have high BODE scores (indicating worse prognoses) might benefit from discussions about end-of-life care and referral to palliative care specialists.

A BODE score is easy to calculate and should be determined for each patient with COPD; it requires measurement of body mass index, spirometry, a 6-minute walk test, and evaluation of MRC dyspnea grade (Table 317). A higher score (out of 10) indicates a worse prognosis. The mortality hazard ratio associated with a 1-unit change in score is 1.34.

View this table:
  • View inline
  • View popup
Table 3

Points used to calculate the BODE index score

Approach to management

It is crucial for physicians to be positive and supportive. Disease-specific education is important for all patients with chronic illnesses. If formal education programs are not available, information booklets on COPD are useful and are available through most provincial lung associations.

Nonpharmacologic therapy for COPD includes smoking cessation, yearly influenza vaccine, pneumonia vaccine every 5 to 10 years, and oxygen therapy (if patients have resting daytime hypoxemia). Smoking cessation counseling should be offered to all patients who continue to smoke. Cessation rates are higher when counseling is combined with smoking cessation aids, such as nicotine replacement therapy22 or newer therapies including bupropion or varenicline.23

The benefits of pulmonary rehabilitation are well recognized1,24 and include decreased dyspnea, increased capacity for exercise, and better quality of life. The main limiting factors are patients’ motivation, the availability of rehabilitation programs, and failure to refer. It is now recognized that patients with all levels of disease can be enrolled in pulmonary rehabilitation programs, although those with more severe muscle weakness and exercise intolerance and less ventilatory limitation are likely better candidates.25 The role of education in COPD management has gained greater importance with the recognition that education and self-management programs substantially reduce the number of nonscheduled clinic visits, emergency room visits, and hospital admissions.26 We recommend that all patients with COPD receive counseling on the importance of regular structured physical activity. Patients should be encouraged to increase their physical activity and recognize that dyspnea is not a sign of harm.

There have been several recent advances in pharmacologic therapy for COPD. Chronic obstructive pulmonary disease is not asthma, and the role of bronchodilator therapy and corticosteroid therapy is unique in the treatment of COPD.

Short-acting bronchodilator therapy (salbutamol and ipratropium) should be used to reduce dyspnea and improve exercise performance and lung function. Combination therapy achieves greater bronchodilation although has no additional effect on dyspnea or quality of life. Long-acting bronchodilator agents, including long-acting β-agonists (salmeterol and formoterol) and the long-acting anticholinergic agent tiotropium provide sustained improvements in lung function while also achieving improvements in dyspnea and quality of life. With greater understanding of the mechanisms responsible for dyspnea in COPD, it is now established that long-acting bronchodilator therapy, particularly tiotropium, exerts its beneficial effect by reducing dynamic hyperinflation and the resulting increased labour of breathing.27 This helps to alleviate dyspnea and improve capacity for exercise. A recent randomized controlled trial demonstrated a small but significant 5.7% absolute reduction in exacerbation rates in patients with severe COPD (mean FEV1 was 36% of predicted) treated with tiotropium compared with those taking placebo.28 The combination of tiotropium and ipratropium might cause excessive drying of the mouth and increased sputum viscosity and should, therefore, be used cautiously, if at all.

Inhaled corticosteroids (ICS) have been recommended for patients with moderate to severe airflow obstruction and frequent exacerbations based on data from randomized controlled trials.29 Recent studies evaluating the effect of ICS on mortality have had conflicting results.30 The TORCH trial, a large (n = 6112), multicentre, randomized controlled trial, failed to show a statistically significant reduction in mortality in any of the treatment arms (fluticasone plus salmeterol, salmeterol alone, fluticasone alone) compared with placebo.31 Use of a combination of an ICS and a long-acting bronchodilator agent, though, has been shown to increase lung function, improve health-related quality of life, and reduce dyspnea compared with use of either agent alone.32

In centres where sputum cell count measurement is available, we recommend measuring total and differential cell counts to evaluate for a concurrent diagnosis of eosinophilic bronchitis, which is present in up to 40% of patients with COPD.33 Identifying these patients is important because they will have a greater response to ICS therapy and might also have a greater reduction in exacerbations while receiving this therapy.33,34

Identifying and managing the systemic manifestations of COPD is extremely important. Patients with pulmonary hypertension secondary to COPD and cor pulmonale require careful fluid and diuretic management while stable and during exacerbations. Patients with chronic hypercapnia are at increased risk of respiratory acidosis and hypercapnic respiratory failure with uncontrolled supplemental oxygen therapy, particularly during exacerbations. Ideally, these patients should be identified while they are stable in order to prevent the complications associated with excessive supplemental oxygen delivery during exacerbations. Patients with low body mass and peripheral muscle dysfunction might benefit more from respiratory rehabilitation than patients whose exercise capacity is limited primarily by their ventilatory function.25 Patients with COPD who have osteopenia or osteoporosis should be identified and treated with calcium, vitamin D, and bisphosphonate therapy, particularly when they have ongoing exposure to corticosteroids. Anxiety or depression can result from symptoms of COPD or arise independently. Anxious or depressed patients require careful evaluation and consideration of reversible causes, including excessive β-agonist use or oral corticosteroid therapy. In some situations, therapy directed at controlling symptoms results in a reduction in dyspnea-related anxiety. We have found it beneficial to involve members of an interdisciplinary health care team, including social workers, psychiatrists, or respiratory therapists, in the care of these patients.

Outpatient management of exacerbations

Recurrent exacerbations are a principal feature of COPD and are defined clinically by increases in dyspnea, sputum volume, or sputum purulence. Exacerbations are associated with a substantial negative effect on quality of life, promote accelerated deterioration in lung function, and are associated with an increased risk of mortality.20 Primary care providers commonly manage outpatient exacerbations of COPD. A chest radiograph should be done if clinically indicated, as it could alter management in up to 20% of cases.35 Corticosteroids have been shown to reduce recurrent exacerbations, decrease length of time in hospital, and improve lung function in patients treated in hospital.36 There is now also strong evidence supporting corticosteroid therapy in outpatient management of exacerbations of COPD, and this therapy should be used routinely unless there are contraindications. Based on evidence from a recent randomized controlled trial,37 we recommend a 7- to 10-day course of prednisone (approximately 30 to 40 mg/d) for patients with exacerbations of COPD not requiring hospitalization. Antibiotics should be given to patients with infective exacerbations of COPD, which are usually characterized by increases in sputum volume and purulence. Patients could also benefit from increased doses of their usual short-acting bronchodilator therapy until the exacerbations resolve, although excessive use of short-acting anticholinergic therapy might cause sputum to become more viscous and make airway clearance more difficult. If an underlying cause is identified (eg, congestive heart failure), then therapy directed toward this cause is warranted. Patients with moderate to severe increases in symptoms or who appear unwell require evaluation in the emergency department and should be considered for hospitalization.

Case resolution

Smoking cessation was discussed, and the woman started taking a long-acting anticholinergic agent (tiotropium) once daily along with a short-acting bronchodilating agent (salbutamol), 2 puffs as needed up to 4 times a day. An exercise program was discussed and recommended. She was seen in follow-up in the fall, and influenza vaccine was provided. The patient reported that she had stopped smoking and had noticed an improvement in her dyspnea and capacity for exercise. She was also very happy to report that she was now able to complete all 18 holes of golf with her friends.

Conclusion

Chronic obstructive pulmonary disease is a common systemic disorder that is preventable, often underdiagnosed, and amenable to therapy. Patients with COPD who suffer from dyspnea could benefit from short- and long-acting bronchodilator agents and respiratory rehabilitation. Application of recent advances in management of COPD in office practice is practical38 and can provide physicians and patients with renewed optimism in managing COPD.

Notes

EDITOR’S KEY POINTS

  • Using a simple approach to identifying and managing chronic obstructive pulmonary disease (COPD) could substantially improve care of patients with COPD and the efficiency of practice.

  • Screening can be carried out with office spirometry. All smokers and ex-smokers 40 years old and older should be screened.

  • Measures other than forced expiratory volume of air in 1 second should be used to establish the severity of disease in primary clinical practice. Another helpful maneuver is to measure dyspnea using the modified Medical Research Council dyspnea scale or BODE index, a multidimensional tool that predicts survival of patients with COPD based on body mass index, forced expiratory volume of air in 1 second, degree of dyspnea, and capacity for exercise.

POINTS DE REPÈRE DU RÉDACTEUR

  • L’utilisation d’une méthode simple pour identifier et traiter la maladie pulmonaire obstructive chronique (MPOC) pourrait améliorer considérablement les soins aux patients atteints et l’efficacité de nos interventions.

  • On peut effectuer le dépistage au bureau par la spirométrie. Tous les fumeurs et ex-fumeurs de 40 ans et plus devraient subir le dépistage.

  • Dans les soins primaires, l’évaluation de la gravité de l’atteinte devrait recourir à des mesures autres que le volume expiratoire maximal/seconde. Une autre manoeuvre utile, qui permet de prédire la survie des patients atteints de MPOC, consiste à mesurer la dyspnée par une modification de l’échelle de dyspnée du Conseil des Recherches Médicales ou par l’indice de Bode, un outil multidimensionnel fondé sur l’indice de masse corporelle, le volume expiratoire maximal/seconde, le degré de dyspnée et la capacité à l’effort.

Footnotes

  • Competing interests

    Dr McIvor has received honoraria for speaking events and attending advisory board meetings of pharmaceutical companies involved in chronic obstructive pulmonary disease, including AstraZeneca, Abbot, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Nycomed, Merck Frosst, and Pfizer. Dr Cox has been sponsored by GlaxoSmithKline, Pfizer, AstraZeneca, and Boehringer Ingelheim to speak to groups of primary care physicians about chronic obstructive pulmonary disease specifically related to the Canadian Thoracic Society’s guideline on management of the disease.

  • Cet article a fait l’objet d’une révision par des pairs.

  • This article has been peer reviewed.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    O’DonnellDEAaronSBourbeauJBourbeauJHernandezPMarciniukDDCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 updateCan Respir J200714Suppl B5B32B
    OpenUrlPubMed
  2. ↵
    GosselinkRTroostersTDecramerMPeripheral muscle weakness contributes to exercise limitation in COPDAm J Respir Crit Care Med199615397680
    OpenUrlCrossRefPubMed
  3. ↵
    Skeletal muscle dysfunction in chronic obstructive pulmonary diseaseA statement of the American Thoracic Society and European Respiratory SocietyAm J Respir Crit Care Med19991594 Pt 2S140
    OpenUrlPubMed
  4. ↵
    LightRWMerrillEJDesparsJAGordonGHMutalipassiLRPrevalence of depression and anxiety in patients with COPD. Relationships to functional capacityChest198587358
    OpenUrlCrossRefPubMed
  5. ↵
    IncalziRACaradonnaPRanieriPBassoSFusoLPaganoFCorrelates of osteoporosis in chronic obstructive pulmonary diseaseRespir Med200094107984
    OpenUrlCrossRefPubMed
  6. ↵
    SinDDManSFWhy are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary diseaseCirculation200310715149
    OpenUrlAbstract/FREE Full Text
  7. ↵
    LacasseYBrooksDGoldsteinRSTrends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic SocietyChest199911630613
    OpenUrlCrossRefPubMed
  8. ↵
    TinkelmanDGPriceDNordykeRJHalbertRJCOPD screening efforts in primary care: what is the yield?Prim Care Respir J200716418
    OpenUrlCrossRefPubMed
  9. ↵
    BuffelsJDegryseJHeymanJDecramerMOffice spirometry significantly improves early detection of COPD in general practice: the DIDASCO studyChest200412513949
    OpenUrlCrossRefPubMed
  10. ↵
    Van SchayckCPLoozenJMWagenaEAkkermansRPWesselingGJDetecting patients at high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study [abstract]BMJ20023241370
    OpenUrlAbstract/FREE Full Text
  11. ↵
    SchirnhoferLLamprechtBVollmerWMAllisonMJStudnickaMJensenRLCOPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Disease (BOLD) studyChest20071312936
    OpenUrlCrossRefPubMed
  12. ↵
    KrahnMChapmanKREconomic issues in the use of office spirometry for lung health assessmentCan Respir J2003103206
    OpenUrlPubMed
  13. ↵
    FinkGMosheSGoshenJKlainmanELebzelterJSpitzerSFunctional evaluation in patients with chronic obstructive pulmonary disease: pulmonary function test versus cardiopulmonary exercise testJ Occup Environ Med200244548
    OpenUrlCrossRefPubMed
  14. ↵
    NishimuraKIzumiTTsukinoMOgaTDyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPDChest2002121143440
    OpenUrlCrossRefPubMed
  15. ↵
    FletcherCMElmesPCFairbairnASWoodCHThe significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working populationBr Med J1959225766
    OpenUrlFREE Full Text
  16. ↵
    OgaTNishimuraKTsukinoMSatoSHajiroTAnalysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health statusAm J Respir Crit Care Med20031675449
    OpenUrlCrossRefPubMed
  17. ↵
    CelliBRCoteCGMarinJMCasanovaCMontes de OcaMMenezRAThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med2004350100512
    OpenUrlCrossRefPubMed
  18. ↵
    ImfeldSBlockKEWederWRussiEWThe BODE index after lung volume reduction surgery correlates with survivalChest20061298738
    OpenUrlCrossRefPubMed
  19. ↵
    CoteCGCelliBRPulmonary rehabilitation and the BODE index in COPDEur Respir J2005266306
    OpenUrlAbstract/FREE Full Text
  20. ↵
    OngKCEarnestALuSJA multidimensional grading system (BODE index) as predictor of hospitalization for COPDChest200512838106
    OpenUrlCrossRefPubMed
  21. ↵
    CoteCGDordellyLJCelliBRImpact of COPD exacerbations on patient-centered outcomesChest2007131696704
    OpenUrlCrossRefPubMed
  22. ↵
    TaylorMCDingleJLPrevention of tobacco-caused disease. In: Canadian Task Force on the Periodic Health ExaminationCanadian guide to clinical preventive health careOttawa, ONHealth Canada199450011
  23. ↵
    GonzalesDRennardSINidesMOnckenCAzoulaySBillingCBVarenicline Phase 3 Study GroupVarenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trialJAMA20062964755
    OpenUrlCrossRefPubMed
  24. ↵
    TroostersTCasaburiRGosselinkRDecramerMPulmonary rehabilitation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20051721938
    OpenUrlCrossRefPubMed
  25. ↵
    TroostersTGosselinkRDecramerMExercise training in COPD: how to distinguish responders from nonrespondersJ Cardiopulm Rehabil200121107
    OpenUrlCrossRefPubMed
  26. ↵
    BourbeauJJulienMMaltaisFRouleauMBeaupreABeginRReduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management interventionArch Intern Med200316358591
    OpenUrlCrossRefPubMed
  27. ↵
    O’DonnellDEFlugeTGerkenFHamiltonAWebbKAguilaniuBEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J20042383240
    OpenUrlAbstract/FREE Full Text
  28. ↵
    NiewoehnerDERiceKCoteCPaulsonDCooperJAKorkuckiLPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331726
    OpenUrlCrossRefPubMed
  29. ↵
    BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ20003201297303
    OpenUrlAbstract/FREE Full Text
  30. ↵
    SinDDManSFDo chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?Curr Opin Pulm Med200713907
    OpenUrlPubMed
  31. ↵
    CalverleyPMAndersonJACelliBFergusonGTJenkinsCJonesPWTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677589
    OpenUrlCrossRefPubMed
  32. ↵
    CalverleyPPauwelsRVestboJJonesPPrideNGulsvikATRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet200336144956
    OpenUrlCrossRefPubMed
  33. ↵
    LeighRPizzichiniMMMorrisMMMaltaisFHargreaveFEPizzichiniEStable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEur Respir J20062796471
    OpenUrlAbstract/FREE Full Text
  34. ↵
    SivaRGreenRHBrightlingCEShelleyMHargadonBMcKennaSEosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trialEur Respir J20072990613
    OpenUrlAbstract/FREE Full Text
  35. ↵
    BachPBBrownCGelfandSMcCroryDManagement of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidenceAnn Intern Med200113460020
    OpenUrlCrossRefPubMed
  36. ↵
    NiewoehnerDEErblandMLDeupreeRHCollinsDGrossNJLightRWEffect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary diseaseN Engl J Med199934019417
    OpenUrlCrossRefPubMed
  37. ↵
    AaronSDVendemheenKLHebertPDalesRStiellIGAhujaJOutpatient oral prednisone after emergency treatment of chronic obstructive pulmonary diseaseN Engl J Med2003348261825
    OpenUrlCrossRefPubMed
  38. ↵
    McIvorALittlePChronic obstructive pulmonary diseaseBMJ2007334798
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Canadian Family Physician: 54 (5)
Canadian Family Physician
Vol. 54, Issue 5
1 May 2008
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Approach to chronic obstructive pulmonary disease in primary care
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Approach to chronic obstructive pulmonary disease in primary care
David C. Todd, R. Andrew McIvor, Stewart O. Pugsley, Gerard Cox
Canadian Family Physician May 2008, 54 (5) 706-711;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Approach to chronic obstructive pulmonary disease in primary care
David C. Todd, R. Andrew McIvor, Stewart O. Pugsley, Gerard Cox
Canadian Family Physician May 2008, 54 (5) 706-711;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Case description
    • Sources of information
    • Screening and diagnosis
    • Classification of severity and prognosis
    • Approach to management
    • Outpatient management of exacerbations
    • Case resolution
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Top studies of 2024 relevant to primary care
  • Approach to steatotic liver disease in the office
  • Foreskin care
Show more Clinical Review

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire